Soleno Therapeutics (NASDAQ:SLNO) Lowered to “Hold” Rating by Wells Fargo & Company

Wells Fargo & Company downgraded shares of Soleno Therapeutics (NASDAQ:SLNO) from a strong-buy rating to a hold rating in a research report report published on Friday morning,Zacks.com reports.

Several other equities research analysts have also issued reports on the company. Wall Street Zen lowered Soleno Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Cantor Fitzgerald lowered shares of Soleno Therapeutics from an “overweight” rating to a “hold” rating and lowered their target price for the company from $123.00 to $53.00 in a research note on Monday, April 6th. Piper Sandler downgraded shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 7th. Wolfe Research lowered shares of Soleno Therapeutics from an “outperform” rating to a “hold” rating in a report on Tuesday, April 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $83.50.

Soleno Therapeutics Stock Performance

Shares of SLNO stock opened at $52.78 on Friday. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of 229.49 and a beta of -2.81. Soleno Therapeutics has a one year low of $29.43 and a one year high of $90.32. The company’s 50-day simple moving average is $39.99 and its 200-day simple moving average is $47.46. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.16. The firm had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Equities analysts anticipate that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Soleno Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SLNO. Avoro Capital Advisors LLC increased its holdings in shares of Soleno Therapeutics by 12.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock worth $134,270,000 after acquiring an additional 322,223 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Soleno Therapeutics in the 4th quarter worth about $38,000. Seven Fleet Capital Management LP bought a new position in Soleno Therapeutics in the 4th quarter worth about $6,023,000. Virtu Financial LLC acquired a new stake in shares of Soleno Therapeutics in the fourth quarter valued at approximately $1,059,000. Finally, Empowered Funds LLC bought a new stake in shares of Soleno Therapeutics during the fourth quarter valued at approximately $69,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

More Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Update on the company’s VYKAT XR observational (real‑world) study adds to the Prader‑Willi treatment narrative and may support longer‑term commercial expectations for VYKAT XR. Soleno’s VYKAT XR Real-World Study Adds Fuel to the Prader-Willi Investment Story
• Neutral Sentiment: Multiple investor‑rights firms are circulating notices about a pending securities class action and the May 5, 2026 lead‑plaintiff deadline; these outreach efforts are routine in securities litigation (they inform potential plaintiffs but do not by themselves change the merits of claims). SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors
• Negative Sentiment: Numerous law firms (Rosen, Hagens Berman, Bragar Eagel & Squire, Bronstein, Schall, Pomerantz, Faruqi, ClaimsFiler, etc.) have issued lead‑plaintiff/class action notices and at least one class action filing has been reported for the March 26–Nov 4, 2025 alleged class period—this increases legal risk, potential distraction, and uncertainty for shareholders. Bronstein, Gewirtz & Grossman LLC Urges Soleno Investors to Act
• Negative Sentiment: An analyst price‑target cut reported April 16 reduced the target by ~36%, signaling lowered analyst expectations and likely contributing downward pressure on sentiment despite the real‑world study update. Soleno Therapeutics (SLNO) price target decreased

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.